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INTRODUCTION
Since its initial description by Duguid and Kennedy in
1930, extrapulmonary small cell carcinoma (EPSCC) is rec-
ognized as a clinicopathological entity distinct from small
cell carcinoma of the lung (SCLC) (1-3). However, it is still
at times confused with metastatic SCLC. The vast majority
of small cell carcinomas (SCC) develop from the lung, but
only 2.5% of SCC are present at extrapulmonary sites (4, 5).
Unlike SCLC, the natural history of most cases of EPSCC
remains uncovered and therefore optimal therapy cannot be
determined (4). 
The clinical course of the tumor in patients with EPSCC,
is generally aggressive and often recurrent (6). The treatment
of patients with EPSCC has been similar to protocols used
SCLC. Because of its relative chemosensitive nature, the ma-
jority of EPSCC patients have been treated with cisplatinum-
based regimens for chemotherapy (7). Because it is a systemic
disease, localized treatment alone promises only limited sur-
vival; therefore, even at early stage, multimodality therapy
is preferred. 
The purpose of our study was to review the experience with
EPSCC with the specific emphasis on clinical features, res-
ponses to treatment and survival.
MATERIALS AND METHODS
Selection of patients
The tumor registry databases at the Yeungnam University
Medical Center and Catholic University of Daegu Medical
Center were reviewed. Between 1998 and 2005, there were
total 818 patients who diagnosed small cell carcinoma and
34 cases were in extrapulmonary sites (4.1%). We retrieved
and reviewed the records of all 34 patients; the variables ana-
lyzed were: demographic findings, ECOG performance sta-
tus, and location of primary tumor, stage, treatment modal-
ity and response to therapy. 
By definition, patients were included if they had no paren-
chymal lung lesion found on chest CT scan, normal sputum
cytology and/or bronchoscopic examination. The histologi-
cal criteria for the diagnosis of EPSCC was similar to that of
SCLC: round to spindle-shaped small cells with dense nuclei,
inconspicuous nucleoli, and sparse cytoplasm (8). All cases
expressed a neuroendocrine antigen such as chromogranin
A and/or synaptophysin as a result of immunohistochemistry
analysis. Patients with a well differentiated neuroendocrine
tumor, mixed histologic type or Merkel cell carcinoma of
the skin were excluded. 
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Clinical Overview of Extrapulmonary Small Cell Carcinoma
The objective of this study was to review the natural history of extrapulmonary small
cell carcinoma (EPSCC) with specific emphasis on clinical features, response to
treatment and survival. The records of all patients (n=34) with EPSCC treated at
Yeungnam University Medical Center and Catholic University of Daegu Medical
Center between 1998 and 2005 were retrieved and reviewed. The primary sites of
tumor were the esophagus and thymus in 6 patients (17.6%) each, pancreas and
stomach in 5 patients each (14.7%); other sites included were the cervix, abdomi-
nal lymph nodes, abdominal wall, bladder, colon, maxillary sinus, nasal cavity, ovary,
parotid gland and liver. Twenty three patients out of 34 had limited disease. The
median survival of all patients was 14 months. Independent prognostic factors in-
cluded stage and primary tumor location. The prognosis for the patients with exten-
sive disease and in the gastrointestinal group was unfavorable. EPSCC is a non
homogeneous disease entity. As a result of its frequent recurrence, multimodal ther-
apy has a better outcome even in cases of limited disease. Combination chemother-
apy plays a central role for treatment of extensive disease in EPSCC. Further mul-
ticenter studies are now needed to determine more details regarding disease sub-
class and optimal treatment modality. 
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Staging, location and clinical response
In most of the cases, treatment was similar to in cases of
SCLC, so, the patients were divided into 2 groups, limited or
extensive disease in accordance with the SCLC staging sys-
tem. Limited disease (LD) was defined as a localized tumor
with or without regional lymph node involvement that was
easily encompassed within a radiation field. Any extension
beyond the locoregional boundaries was defined as extensive
disease (ED) (2). 
Assessment of response was carried out using the criteria
of World Health Organization criteria. Complete response
(CR) was defined as complete resolution of disease by physi-
cal and radiographic examination, absence of new lesions and
disease related symptoms. Partial response (PR) was defined
as ≥50% reduction in the sum of the products of perpen-
dicular measurements of all sites of measurable disease; pro-
gressive disease (PD) was defined as a ≥25% increase. Sta-
ble disease (SD) was defined by any condition other than objec-
tive response or PD.
Statistical analysis
The SPSS version 11.5 was used for the statistical analysis
of a correlation between factors such as ECOG, sex, chemother-
apeutic regimen, age, location of tumor and overall survival
or response to therapy. The correlation of factors and response
to therapy were assessed using the Fischer’s exact test; the
factors correlated to survival were evaluated using the Log-
rank test for univariate analysis. We used Cox-regression anal-
ysis for multivariate analysis. Survival was analyzed as the
time from diagnosis to death or last follow up. Overall sur-
vival was estimated by the Kaplan-Meier methods. 
RESULTS
Patient characteristics
All 34 patients were enrolled; 23 patients were male (67.6
%) and the other 11 were female (32.4%). The median age
was 56 yr (range, 26-87 yr). Twenty patients (59%) were older
than 60 yr of age. Twenty one patients were smokers and
among them, 20 patients (95%) were men. All patients had
a good performance scale, ECOG 1 or 2. 
The primary sites for EPSCC in this series were: the esoph-
agus in 6 patients (17.6%), the thymus in 6 patients (17.6%),
the stomach in 5 patients (14.7%), the pancreas in 5 patients
(14.7%), the cervix in 2 patients (5.9%); there was 1 patients
each (2.9%) for the following sites: abdominal lymph node,
abdominal wall, bladder, colon, maxillary sinus, nasal cavi-
ty, ovary, parotid gland, prostate and liver. There were more
than 50% EPSCC located in the gastrointestinal (GI) tract.
So we divided two group: GI group versus non-GI group to
evaluate the prognostic factors.
There were 23 patients in the LD and 11 patients were in
the ED at diagnosis (Table 1). Comparisons of the GI group
versus the non-GI group: there were 11 patients in LD GI
group, 7 patients in ED GI group, and 12 patients in LD
non-GI group and 4 patients in ED non-GI group, showed
no statistically significant difference for the stage at diagno-
sis between the two groups (p=0.477).
After the initial evaluation and confirmation of the histo-
logical diagnosis, 1 patient was lost to follow up. 
Charicteristics
Patients
No. %
Age (yr)
<60 14 41
≥60 20 59
Sex
Male 23 67.6
Female 11 32.4
Smoking
Smoker 21 61.8
Non smoker 13 38.2
ECOG
0- -
1 23 67.6
2 11 32.4
3- -
4- -
Stage
LD* 23 67.6
ED
� 11 32.4
Location
Esophagus 6 17.6
Thymus 6 17.6
Stomach 5 14.5
Pancreas 5 14.5
Cervix 2 5.8
Others
� 10 29
Table 1. Patient characteristics 
*limited disease; 
� extensive disease; 
� abdominal lymph node, bladder,
colon, intraabdominal wall, liver, maxillary sinus, nasal cavity, ovary, parotid
gland, prostate.
Regimen
Patients
No. %
Etoposide /Cisplatin 13 38.2
Camptothecin/Cisplatin 13 38.2
Etoposide/Carboplatin 3 8.8
Adriamycin/Cisplatin/Vincristin/Alkyloxan (ADOC) 2 5.8
Alkyloxan/Adriamycin/Vincristin (CAV) 2 5.8
Alkyloxan/Adriamycin/Vincristin/Etoposide+ADOC 1 2.9
Gemzar/UFT 1 2.9
Paclitaxel/Cisplatin 1 2.9
Ifosfamide/Cisplatin 1 2.9
Table 2. Chemotherapy regimenExtrapulmonary Small Cell Carcinoma 835
Response, relapse and treatment
Among the 23 patients in the LD, 1 patient was lost to fol-
low up. Six patients (26%) had received curative resection with
adjuvant chemotherapy and 2 patients (9%) received surgery
plus concurrent chemoradiotherapy. Five patients (22%) had
received concurrent or sequential adjuvant radiotherapy with-
out surgical resection. Four patients received chemotherapy
alone and 2 patients received surgical treatment without che-
motherapy and only 1 patient received radiotherapy without
chemotherapy. Two patients received only supportive care due
to advanced age and refusal of other treatment. Three patients
with LD are still alive and remain in a disease free state. 
As in SCLC, the most commonly used chemotherapy reg-
imen was the combination of etoposide and platinum com-
pounds (cisplatin or carboplatin) (Table 2). Patients in LD
tended to receive multimodality therapy compared to the
patients in the ED. Four patients (36%) with ED were treat-
ed with systemic chemotherapy alone. The other five patients
(45%) also received combination chemotherapy with pallia-
tive surgery or radiotherapy. There were 2 patients who had
no treatment. 
Because the treatment modality for LD varied extensively,
we had too few patients to decide the response. Among pati-
ents in ED, the response was CR in 1 patient, PR in 2 pati-
ents, SD in 4 patients and PD in 2 patients. Including CR and
PR, the response rate (RR) for ED patients was about 33%.
Statistically significant factors that correlated to the response
were not identified in our study by univariate analysis.
Sixteen patients out of the 23 patients who showed response
above SD relapsed. Nine patients showed locoreginal recur-
rence, 4 patients metastasized to brain, 2 patients showed
multiple bone metastasis and 1 patient progressed to liver
metastasis.
Survival
The survival curve for all patients is demonstrated in Fig. 1.
The median survival was about 14 months (95% CI 7.88-
20.96 months). The one year survival rate was about 56%.
In some disease such as lymphoma and acute myeloid leu-
kemia, the age 60 yr has an independent role for prognosis, so
we divided the age groups into an older or younger, with 60
yr as the cut off, for analyzing the correlation of age to sur-
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Fig. 1. Kaplan-Meier plots for overall survival of all enrolled patients.
C
u
m
u
l
a
t
i
v
e
 
s
u
r
v
i
v
a
l
 
r
a
t
e
1.0
0.8
0.6
0.4
0.2
0.0
01 02 03 04 05 06 07 0
Months after diagnosis
Fig. 2. Survival curve by the stage.
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Fig. 3. Overall survival by tumor location (GI group vs. non-GI group).
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Fig. 4. Survival curve according to stage and tumor locations.
ED in GI group
p=0.00
ED in non-GI
LD in GI
LD in non-GIvival. Among the factors studied: ages, stage at diagnosis
and tumor location were the factors statistically significant
in comparison to survival (p=0.0353, p=0.0001 and p=0.0001
respectively). According to multivariate analysis, stage and
tumor location also played roles as independent prognostic
factors for survival (p=0.00 both), however, age did not have
statistical significance (p=0.112). 
The median survival for the patients with LD was 19.8
months (95% CI 5.2-34.5 months). On the other hand, in
patients with ED, the survival was about 7 months (95% CI
4.6-9.7 months). The differences between them in survival
were statistically significant (Fig. 2). The median survival for
the GI group was shorter than that of non-GI group. The me-
dian survival for the GI group was 8 months (95% CI 6.2-
10 months) and for the non-GI group, was 44.6 months (95%
CI, 19.7-69.5) (Fig. 3). We also evaluated the four groups;
LD in GI group, LD in non-GI, ED in GI and ED in non-GI,
and the survival was 13.4 months, 44.6 months, 5.2 months
and 11.3months each other (log rank p=0.00) (Fig. 4).
DISCUSSION
Thirty four patients with EPSCC were reviewed and ana-
lyzed in our study. EPSCC is a very rare clinicopathological
entity (9). In general, the clinical course of this tumor is very
aggressive and often recurs after treatment (6). 
According to the previous studies, tumors develop from
throughout the body in areas such as the head and neck, pan-
creas, cervix, kidney, urinary tract, prostate and esophagus
(10-13). In our study, the most common location for EPSCC
were the esophagus (6 patients 17.6%) and the thymus (6
patients 17.6%). The stomach and pancreas accounted for 5
patients each (14.7%). The other sites involved were: cervix,
prostate, maxillary sinus, nasal cavity, abdominal lymph nodes,
abdominal wall, colon, liver and parotid gland. The prevalence
of involved sites is different at different institutions (14). 
Among 34 patients, more than 67% of the patients were
men (23 patients) and approximately 61.8% of the affected
patients had a history of smoking, and 95% of smokers were
men. Some studies have suggested that cigarette smoking is
associated with EPSCC of particular sites especially the head
and neck or esophagus (4). Our study also showed a tendency
for this correlation but could not conclude definitively because
of the limitations of the retrospective study.
Patients with LD in our study were likely to receive radi-
cal surgery or radiotherapy followed by adjuvant chemothera-
py. Patients in LD group were considered to have systemic
disease therefore, systemic chemotherapy was needed after
local treatment. Multimodality therapy is required for the
majority of patients with LD to improve overall outcome (15).
For patients with ED regardless of site of origin, systemic
combination chemotherapy is the most appropriate treatment
modality (16, 17). The chemotherapeutic regimens used for
treatment of EPSCC were similar to those of SCLC (18). The
most common regimens used in our study were the combina-
tion of etoposide-cisplatinum (13 patients; 38.2%) or camp-
tothecin-cisplatinum (13 patients; 38.2%). 
The response to treatment and median survival in group
of patients with this therapy has been disappointing (2). In
our study, the response rate of the ED patients was only 33%,
more unfavorable than other reports. The cause for the dis-
appointing results requires further study for explanation.
There were no statistically significant factors that correlated
with the treatment response. 
The median survival for all patients was 14 months (95%
CI 7.9-21.0). The stage at diagnosis and location of disease,
especially for the GI group were independent prognostic fac-
tors of survival. The overall survival of the patients with LD
was more favorable than for the patients with ED (p=0.0001).
In case of LD, more than 50% patients received operation or
radiotherapy for local control, maybe it is the main cause of
the difference in survival. The overall survival for ED EPSCC
in this study was 7 months, and was different from survival
for SCLC in ED. The result of EPSCC was unfavorable than
SCLC. In SCLC, the median survival of ED patients was about
9 to 12 months (7). The overall survival for patients with SCC
of the GI tract was shorter than non-GI tract SCC. SCC of
the GI tract is rare and most commonly found in patients of
advanced age; previous reports suggest a dismal prognosis
(4, 19). The range of median survival is reported to be from
several weeks to 6-12 months (20-22). In our study, the medi-
an survival of GI group was about 8 months. There were no
significant factors identified to differentiate the GI group from
the non GI group in our study. 
The patients in LD of non-GI group has the longest sur-
vival. EPSCC is not metastatic SCLC but similar treatment
modalities are used in both disorders; the response and over-
all survival is not the same. Combination chemotherapy is
considered the treatment of choice for EPSCC: however, active
local treatment also has an important role in LD EPSCC.
Our study has several limitations related to the retrospec-
tive design and the small number of patients. However, the
overall survival and independent prognostic factors closely
resemble other reports (2). Further prospective multicenter
studies are required for better understanding of disease enti-
ties and response to treatment modalities. 
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